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fusion-treated patient but the average epoetin-and-
transfusion-free costs were very similar in the two groups.
The costs varied highly between centres, but a high EAI
independently decreased the without-epoetin-costs by
15%. CONCLUSIONS: An appropriate and homoge-
neous use of epoetin might reduce the costs of cancer
treatment.
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The recent introduction on the French market of 
HerceptinTM, an innovative drug associated to a high
acquisition cost, justiﬁes its economic assessment.
OBJECTIVE: The study aim was to compare 8 chemo-
therapies as ﬁrst-line treatment in MBC (doxorubicin 
(D) + cyclophosphamide (C); 2 combinations of 5-
Fluorouracile (F), Epirubicin (E) and C i.e. FEC50 and
FEC100; D + paclitaxel (P); D + docetaxel (T); E + P; 
E + T; H + P. METHODS: The study methodology,
according to a French payer perspective, is a cost-
effectiveness analysis based on a decision tree model.
Assessment considers the period from the diagnosis of
metastasis until the end therapy or death. The clinical
data are obtained from recently published phase III ran-
domised trials. Effectiveness was assessed through time to
progression criteria. Chemotherapy procedures, incidence
of adverse events, patient transport and nurse care follow
up were collected. Hospital costs were estimated through
the National Costs References per DRG. Medication
costs were estimated from standard dosages. General
Nomenclature of Practitioner Acts (NGAP) was used to
valuate ambulatory follow-up care. A sensibility analysis
was led on efﬁcacy criteria and main drivers cost.
RESULTS: The mean cost by week without progression
is €550 for H + P, €424 for E + T, €417 for E + P, €418
for D + T, €438 for D + P, €374 for FEC50, €324 for
FEC100 and €365 for D + C. The most effective combi-
nation appears to be E + T, as and the ﬁnancial sacriﬁce
associated with an additional one week without progres-
sion, as compared to FEC100 for instance, is €895.
Anthracyclins (D or E) + taxans (P or T) combinations
show a complete dominance when compared to the H +
T strategy, but the latter is only offered to the subpopu-
lation of patients showing the receptor over-expression, a
potential negative predictor for response to chemo-
therapy. CONCLUSIONS: Although this type of analysis
favours the use of anthracyclins + taxans combinations in
ﬁrst-line treatment of MBC, our hypothesis has to be con-
ﬁrmed by clinical pharmaco-economical trials.
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OBJECTIVES: Gemcitabine/cisplatin (GC) is one of
many novel chemotherapy regimens available for the
treatment of non-small cell lung cancer. This study con-
ducted two clinical trial-based economic evaluations 
comparing GC with other novel agent regimens in ﬁve
European countries: France, Germany, Italy, Spain, and
the UK. METHODS: The economic evaluations were
conducted using evidence from two randomised, con-
trolled trials of GC and the other novel regimens. The ﬁrst
analysis was based upon the trial published by Comella
et al. (2000) and compared GC with vinorelbine/cisplatin
(VC). The second analysis was based upon the trial pub-
lished by Schiller et al. (2000) and compared GC with
paclitaxel/cisplatin (PCI), paclitaxel/carboplatin (PCA)
and docetaxel/cisplatin (DC). In these trials, pivotal
health outcomes including overall and progression-free
survival were similar between GC and the other regimens
meaning cost-minimisation analysis was employed.
RESULTS: The analysis based on Comella et al. (2000)
found that GC was associated with lower total treatment
costs than VC in all ﬁve countries. The overall cost
savings associated with GC ranged from €802 in Spain to
£1,262 in the UK. The second analysis found that GC had
lower total treatment costs than both of the paclitaxel
regimens in all ﬁve countries. The overall cost savings 
for GC were greatest when compared against PCA and
ranged from €2,153 in Italy to €4,846 in France. GC was
associated with a small incremental cost compared to DC
in Germany (€95 per patient) and was cost saving in the
other four countries. CONCLUSIONS: GC was associ-
ated with lower total treatment costs than VC, PCI and
PCA from the perspective of the national health services
of ﬁve European countries. Given similar efﬁcacy ﬁndings
in these studies, a claim for cost-effectiveness of GC in
the treatment of advanced NSCLC is supported.
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OBJECTIVE: A number of new agents have become
available in the past decade for the treatment of non-
